Literature DB >> 28087540

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

David C Fajgenbaum1, Thomas S Uldrick2, Adam Bagg3, Dale Frank3, David Wu4, Gordan Srkalovic5, David Simpson6, Amy Y Liu1, David Menke7, Shanmuganathan Chandrakasan8, Mary Jo Lechowicz8, Raymond S M Wong9, Sheila Pierson1, Michele Paessler10, Jean-François Rossi11, Makoto Ide12, Jason Ruth13, Michael Croglio14, Alexander Suarez1, Vera Krymskaya15, Amy Chadburn16, Gisele Colleoni17, Sunita Nasta18, Raj Jayanthan19, Christopher S Nabel20, Corey Casper21, Angela Dispenzieri22, Alexander Fosså23, Dermot Kelleher24, Razelle Kurzrock25, Peter Voorhees26, Ahmet Dogan27, Kazuyuki Yoshizaki28, Frits van Rhee29, Eric Oksenhendler30, Elaine S Jaffe2, Kojo S J Elenitoba-Johnson3, Megan S Lim3.   

Abstract

Human herpesvirus-8 (HHV-8)-negative, idiopathic multicentric Castleman disease (iMCD) is a rare and life-threatening disorder involving systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6. iMCD accounts for one third to one half of all cases of MCD and can occur in individuals of any age. Accurate diagnosis is challenging, because no standard diagnostic criteria or diagnostic biomarkers currently exist, and there is significant overlap with malignant, autoimmune, and infectious disorders. An international working group comprising 34 pediatric and adult pathology and clinical experts in iMCD and related disorders from 8 countries, including 2 physicians that are also iMCD patients, was convened to establish iMCD diagnostic criteria. The working group reviewed data from 244 cases, met twice, and refined criteria over 15 months (June 2015 to September 2016). The proposed consensus criteria require both Major Criteria (characteristic lymph node histopathology and multicentric lymphadenopathy), at least 2 of 11 Minor Criteria with at least 1 laboratory abnormality, and exclusion of infectious, malignant, and autoimmune disorders that can mimic iMCD. Characteristic histopathologic features may include a constellation of regressed or hyperplastic germinal centers, follicular dendritic cell prominence, hypervascularization, and polytypic plasmacytosis. Laboratory and clinical Minor Criteria include elevated C-reactive protein or erythrocyte sedimentation rate, anemia, thrombocytopenia or thrombocytosis, hypoalbuminemia, renal dysfunction or proteinuria, polyclonal hypergammaglobulinemia, constitutional symptoms, hepatosplenomegaly, effusions or edema, eruptive cherry hemangiomatosis or violaceous papules, and lymphocytic interstitial pneumonitis. iMCD consensus diagnostic criteria will facilitate consistent diagnosis, appropriate treatment, and collaborative research.

Entities:  

Mesh:

Year:  2017        PMID: 28087540      PMCID: PMC5364342          DOI: 10.1182/blood-2016-10-746933

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  Autoimmune cytopenias in Castleman's disease.

Authors:  P A Carrington; H Anderson; M Harris; S E Walsh; J B Houghton; G R Morgenstern
Journal:  Am J Clin Pathol       Date:  1990-07       Impact factor: 2.493

Review 2.  [Castleman's disease and glomerular nephropathy (apropos of 1 case].

Authors:  C Combe; J L Bouchet; L Potaux; D Morel; C Deminière; J M Coindre; M Aparicio
Journal:  Nephrologie       Date:  1989

3.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients.

Authors:  E Oksenhendler; G Carcelain; Y Aoki; E Boulanger; A Maillard; J P Clauvel; F Agbalika
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

4.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Authors:  N Nishimoto; M Sasai; Y Shima; M Nakagawa; T Matsumoto; T Shirai; T Kishimoto; K Yoshizaki
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

5.  Cutaneous castleman's disease responds to anti interleukin-6 treatment.

Authors:  Bilal Ahmed; Jaime A Tschen; Philip R Cohen; Mohamed H Zaki; Peter L Rady; Stephen K Tyring; Robert E Corringham; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2007-08-31       Impact factor: 6.261

6.  Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Girish Venkataraman; Thomas S Uldrick; Karen Aleman; Deirdre O'Mahony; Donald S Karcher; Seth M Steinberg; Mark A Raffeld; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan; Stefania Pittaluga; Irina Maric
Journal:  Am J Clin Pathol       Date:  2013-05       Impact factor: 2.493

Review 7.  Castleman Disease of the Thorax: Clinical, Radiologic, and Pathologic Correlation: From the Radiologic Pathology Archives.

Authors:  Seth J Kligerman; Aaron Auerbach; Teri J Franks; Jeffrey R Galvin
Journal:  Radiographics       Date:  2016 Sep-Oct       Impact factor: 5.333

8.  Angiofollicular lymph node hyperplasia: a comparison of unicentric, multicentric, hyaline vascular, and plasma cell types of disease by morphometric and clinical analysis.

Authors:  D M Menke; J K Camoriano; P M Banks
Journal:  Mod Pathol       Date:  1992-09       Impact factor: 7.842

Review 9.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

10.  Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome.

Authors:  Shotaro Tatekawa; Koji Umemura; Ryuichi Fukuyama; Akio Kohno; Masafumi Taniwaki; Junya Kuroda; Yoshihisa Morishita
Journal:  Clin Case Rep       Date:  2015-04-22
View more
  125 in total

Review 1.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Unraveling Castleman: progress in a complex process.

Authors:  Kieron Dunleavy
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

3.  Sjögren's and plasma cell variant Castleman disease: a case report.

Authors:  Yvonne A Dei-Adomakoh; Leslie Quarcoopome; Afua D Abrahams; Catherine I Segbefia; Dzifa I Dey
Journal:  Ghana Med J       Date:  2018-03

4.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.

Authors:  Sang-Hoon Sin; Anthony B Eason; Rachele Bigi; Yongbaek Kim; SunAh Kang; Kelly Tan; Tischan A Seltzer; Raman Venkataramanan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

5.  Somatic Mutations Confer Severe Peripheral Neuropathy in POEMS Syndrome-Associated Multicentric Castleman Disease.

Authors:  Qingqing Lin; Juying Wei; Jiejing Qian; Liangshun You; Wenbin Qian
Journal:  Neurosci Bull       Date:  2020-03-12       Impact factor: 5.203

Review 6.  TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.

Authors:  Gordan Srkalovic; Inga Marijanovic; Maya B Srkalovic; David C Fajgenbaum
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

7.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

8.  Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Ruth-Anne Langan; Alberto Sada Japp; Helen L Partridge; Sheila K Pierson; Amrit Singh; Daniel J Arenas; Jason R Ruth; Christopher S Nabel; Katie Stone; Mariko Okumura; Anthony Schwarer; Fábio Freire Jose; Nelson Hamerschlak; Gerald B Wertheim; Michael B Jordan; Adam D Cohen; Vera Krymskaya; Arthur Rubenstein; Michael R Betts; Taku Kambayashi; Frits van Rhee; Thomas S Uldrick
Journal:  J Clin Invest       Date:  2019-08-13       Impact factor: 14.808

Review 9.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

Review 10.  Biologic Agents in the Treatment of Multicentric Castleman Disease.

Authors:  Konstantinos Kapriniotis; Savvas Lampridis; Sofoklis Mitsos; Davide Patrini; David R Lawrence; Nikolaos Panagiotopoulos
Journal:  Turk Thorac J       Date:  2018-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.